Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (289)	3/4/1999 9:00:00 AM
From: Thomas Kirwin	Respond to of 422

Gamma Earnings Contribution Mason, Gamma reported the following earnings for their fiscal year end 1998.... "HOUSTON, May 22, 1998-----Gamma Biologicals, Inc. (Amex: GBL) today reported that, for the fiscal year ended March 31, 1998, the company earned $1,310,000 (28 cents per share – diluted) on net sales of $18, 254,000 compared with net income of $1,116,000 (24 cents per share – diluted) on net sales of $17,555,000 for the year ended March 31, 1997. Fiscal 1998 pretax income included $1,154,000 benefit related to the September 1997 fire at the company's facility." "For the fourth quarter ended March 31, 1998, net income was $161,000 (three cents per share – diluted) on net sales of $4,414,000 compared with net income of $234,000 (five cents per share – diluted) on net sales of $4,516,000 for the same period last year." It is my best guess that Immucor has cut expenses in the neighborhood of $2.8 million translating into a positive $700,000 quarterly impact on the bottom line. Given the fact that Gamma's SG&A expenses were negatively affecting the bottom line, lets assume that they were at breakeven when acquired by Immucor. Conservatively, the merger could add anywhere between $0.2 - $0.3 per quarter to Immucor's bottom line. Should Gamma repeat its past performance and generate $1,310,000 in net income there is some real upside potential even when considering the loan acquisition expense. Such a feat could produce $0.4 - $0.5 eps per quarter. The above calculations were based on outstanding shares of 7.5 to 8.0 million as I do not have that info readily available. Note - Please check my napkin math! IMHO - I'd rather err on the conservative side but believe that we could be pleasantly surprised. Regards, Tom

To: Mason Barge who wrote (289)	3/4/1999 5:06:00 PM
From: Thomas Kirwin	Respond to of 422

Speaking of Strategic Alliances.... I wonder when Immucor and Sanguin International will announce their joint internet venture to the world or at least the blood bank & serology industry. Perhaps there is a blood industry convention scheduled in the near future that may afford the correct venue to introduce Ready-Id.com. Convention Calendar aabb.org My best guess is that this web site could generate a few million dollars in extra revenue and profits as it is just an extension of Immucor's customer service unit already established. I suspect that operating such an automated web site is inexpensive. ready-id.com Regards, Tom P.S. Could Immucor & Sanguin or Bio-Tek be courting? Bio-Tek Web Site biotek.com